ADVERSE EFFECTS OF GLP-1 RECEPTOR AGONISTS: A COMPREHENSIVE APPROACH

Introduction and Aim: Glucagon‑like peptide‑1 (GLP‑1) receptor agonists have recently witnessed a substantial rise in popularity. Originally developed for the treatment of type 2 diabetes mellitus (T2DM), their therapeutic indications have now broadened considerably. Their beneficial impact has been documented not only on the quality of life in patients with T2DM, but also in those with chronic kidney disease (CKD), cardiovascular disease, and obesity. These are not the only current indications for GLP‑1 analogs, and it remains to be seen what additional conditions may benefit from these agents in the future. Given their well‑documented mechanisms of action and widespread clinical use, it is im-portant to scrutinize these medications more closely. The objective of this review is to analyze the ad-verse effects associated with GLP‑1 analog therapy. Materials and Methods: A literature search was conducted using the PubMed and Google Scholar databases, focusing on novel publications from the past five years. Conclusions: Current evidence regarding adverse events remains inconclusive, underscoring the need for further investigation. For instance, while some studies suggest an elevated risk of thyroid cancer, other meta‑analyses draw entirely opposite conclusions. This unequivocally indicates a strong need for further analysis.